Neal Seth

Neal Seth is a partner at Wiley Rein LLP in Washington, D.C., where he is the head of the firm's Patent Litigation Practice. His practice is heavily focused on intellectual property and commercial matters, with a particular specialization in pharmaceutical patent litigation. Seth has extensive experience as lead counsel in Hatch-Waxman (ANDA) litigation, representing clients in cases involving well-known drugs such as apixaban (Eliquis), rivaroxaban (Xarelto), aripiprazole (Abilify), and lenalidomide (Revlimid). Beyond his pharmaceutical work, he has also handled patent cases related to computer forensic devices and other technologies in U.S. District Courts and the International Trade Commission (ITC).

The provided data indicates Seth has primarily represented defendants, which is consistent with a practice centered on ANDA litigation for generic pharmaceutical clients. His firm biography and representative cases confirm significant experience defending against patent infringement claims. In addition to his district court and ITC work, Seth is described as having extensive experience in inter partes reviews (IPRs) before the Patent Trial and Appeal Board (PTAB). The single tracked case, Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., shows him defending Glenmark.

Prior to his current role, it appears the authoritative data may be based on a past firm association, though his public profiles are now exclusively centered on his long-standing practice at Wiley Rein LLP. He has been recognized as a leading practitioner in his field, having been named to Bisnow's "Top 40 Lawyers Under 40" in the Washington, D.C. area in 2016.

Seth earned his J.D. from The George Washington University Law School and his B.S. from Cornell University.